ANNUALLY IN THE US
SUFFER DELAYED OR POOR RESPONSE TO THERAPY
WITHIN 30 DAYS
Heart failure (HF) is a chronic, progressive disease in which the heart is unable to pump enough oxygen-rich blood to the body. Acute HF is the sudden worsening of this condition, mostly due to fluid congestion. Increase in blood volume elevates vascular pressure and affects the kidneys’ ability to exert urine and sodium, causing build-up in the extremities (edema), lungs (dyspnea), and other internal organs.
The key treatment is diuretic therapy, aimed at increasing the patient’s urine and sodium output.
Poor or delayed response to diuretics leads to increased mortality, longer hospitalization, and higher 30-day re-admission rates. This direct financial impact is not reimbursed to the hospitals, with potential added risk from The Affordable Care Act penalties.
The Doraya catheter is designed to improve the efficacy of diuretic therapy in patients with acute heart failure (AHF). A manageable flow-reducing Central Venus Catheter, Doraya is deployed in the infrarenal IVC for up to 12 hours, helping cardiologists to temporarily manage venous hemodynamics, central venous pressure, renal afterload, and venous returns. Data from the Doraya First in Human feasibility study was presented at THT 2022 and featured in the March 2022 release of the Journal of the American College of Cardiology: Basic to Translational Science, demonstrating promising results.
To see the full research letter [Download PDF].
efficacy and urine output
Improved clinical signs
(edema, ascites, dyspnea)
Reduced length of
Revamp medical was founded in 2016 with the goal of resolving one of the most urgent unmet needs in Acute Heart Failure patients. We believe that by using Doraya, cardiologists can enhance patient response to diuretic therapy, thereby rapidly alleviate signs and symptoms of congestion, improving patient outcomes and significantly reducing the financial burden of readmission. Revamp has a seasoned team of professionals with a proven track record in leading multiple med-tech startups.
CRF, Director of Heart Failure, Hemodynamics and Mechanical Circulatory Support Research.
Section Head, Heart Failure, Cardiac Transplantation and Mechanical Circulatory Support, Montefiore MC, NY. Serves as Chair of the Mechanical Circulatory Support Council of the International Society of Heart and Lung Transplantation.
Director of Advanced Heart Failure and Cardiac Transplantation at NewYork-Presbyterian, USA
Head of the Cardiology Department at the Centre for Heart Diseases at the 4th Military Hospital, Wroclaw, Poland. He was the committee chairman of the ESC Guidelines on the Diagnosis and Treatment of Acute and Chronic Heart Failure (2016).
Revamp Medical Ltd. 5 Mefi, Netania, Israel, 4250489
T: +972-73-3819227 | firstname.lastname@example.org
This project has received funding from the European Union’s Horizon 2020 SME Instrument program under grant agreement nr 855362.